FDA approves angiotensin II formulation (Giapreza) for blood pressure maintenance in adults with refractory septic shock
The US Food and Drug Administration (FDA) has approved an angiotensin II intravenous formulation (Giapreza, La Jolla Pharmaceutical Co) for the treatment of hypotension in adults with refractory distributive and septic shock not responsive to IV fluids and other vasopressors. Giapreza will become available on the US market in March of 2018. Approval of Giapreza [...]
Back in April of this year I wrote a blog on the discovery by Dr. Paul Marik, a critical care physician at East Virginia Medical School, that a cocktail of vitamin C, hydrocortisone and thiamine was remarkably effective at treating patients with severe sepsis and septic shock. Results with use of Marik’s cocktail were so [...]
Background A definitive cure for sepsis has eluded physicians and scientists since the advent of modern medicine. Over the years, numerous agents have undergone testing in clinical trials, but most have shown limited to no efficacy for the treatment of this deadly condition. The recombinant activated protein C, dtrotrecogin alfa (Xigris), was FDA approved for [...]
As many of you know, September is Sepsis Awareness Month, a time when many hospitals and healthcare professionals and organizations throughout the world come together to increase public and professional awareness of sepsis. Although great strides have been made in recent years in its early recognition and treatment, sepsis is still far too common and [...]
Recently, we’ve been making a number of important updates to the content of our Sepsis app that we would like to briefly review here. These updates have been made to the English version of the Sepsis app and will soon be made to the Spanish version in the coming days. First, we have updated the definitions [...]
An expert 19-member task force convened by the Society of Critical Care Medicine (SCCM) and the European Society for Intensive Care Medicine (ESICM) has announced new definitions for sepsis and septic shock at the 45th annual Critical Care Congress currently taking place in Orlando, Florida. The new definitions, referred to as Sepsis-3, have also been [...]
It has been a while since our last blog post and we never bother our users with appeals, but we think this is very important. Please take a few minutes to read this post and vote for sepsis! The NASCAR Foundation has selected Dr. Carl Flatley, founder of the Sepsis Alliance, as one of four [...]
The long-awaited results of the Protocolized Care for Early Septic Shock (ProCESS) multicenter, randomized clinical trial were released today in the March 2014 issue of the New England Journal of Medicine. ProCESS compared mortality and other outcomes in 1341 patients with septic shock treated using three different approaches: Protocol-based early goal-directed therapy (EGDT): Protocol required [...]
We want to remind participants in the IMPRESS study that there are now fewer than 2 DAYS left until its start. IMPRESS is an observational study designed to assess the incidence and clinical patterns of septic syndromes on a single day, November 7th, in ICUs and emergency departments worldwide. Registered site investigators should have received [...]
IMPRESS (International Multicentre PREvalence Study on Sepsis) is an observational study on sepsis and septic shock sponsored by the European Society of Intensive Care (ESICM) and the Society of Critical Care Medicine (SCCM). IMPRESS will analyze de-identified patient data from participating facilities (ERs or ICUs) worldwide from patients admitted with severe sepsis or septic shock [...]
- FDA approves angiotensin II formulation (Giapreza) for blood pressure maintenance in adults with refractory septic shock
- Looking for the Vitamin C sepsis cure – An interview with Paul Marik
- Could vitamin C be the miracle cure for sepsis?
- September is Sepsis Awareness Month – help educate your peers and patients!
- Important updates to Sepsis app content